BWA
AKBA icon

Basecamp Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

Basecamp Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205 Sell
180
-210
-54% -$250 ﹤0.01% 1737
2026
Q1 		$542 Buy
+390
New +$536 ﹤0.01% 1706

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Basecamp Wealth Advisors's AKBA Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Akebia Therapeutics (AKBA) stake by 54% in Q2 2026, selling an estimated $250 and leaving 180 shares worth $205. The position accounts for ﹤0.01% of the portfolio, ranked #1737.

Basecamp Wealth Advisors first reported a position in AKBA in Q1 2026 and has held it in 2 quarters since. The position peaked at $542 in Q1 2026. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Basecamp Wealth Advisors held 180 shares of Akebia Therapeutics worth $205 as of Q2 2026.
  • Basecamp Wealth Advisors sold 210 Akebia Therapeutics shares in Q2 2026, an estimated $250.
  • Akebia Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1737 holding.
  • Basecamp Wealth Advisors first reported a position in Akebia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Basecamp Wealth Advisors's Akebia Therapeutics position peaked at $542 in Q1 2026.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.